ISSN 1866-8836
Клеточная терапия и трансплантация

Optimal management of adolescents with acute lymphoblastic leukaemia

Giorgio Dini, Stefano Giardino, Simone Dini

Dept. of Pediatric Hematology and Oncology, IRCCS “G.Gaslini”, Genoa, Italy

Correspondence
Giorgio Dini, MD, Dept. of Pediatric Hematology and Oncology, IRCCS “G.Gaslini”, Largo G. Gaslini, 5, 16148, Genoa, Italy
Phone: +39 (010) 5636715, fax: +39 (010) 3777133, E-mail: giorgiodini@ospedale-gaslini.ge.it
doi 10.3205/ctt-2009-No5-abstract71

Download PDF version

Cellular Therapy and Transplantation (CTT)
Volume 2, Number 1(5)
Contents 

Summary

During the last 25 years, improvement in survival for young children with acute lymphoblastic leukaemia (ALL) has been striking: children aged 1 to 9 years have the best outcome. However, children and adolescents aged 10 to 20 years have a markedly worse outcome, which is associated – in part – with genetic abnormalities, a lower incidence of favourable genetic abnormalities such as TEL/AML1 and hyperdiploidy, and a higher incidence of T-cell leukaemia.

Adolescents are less likely to have access to healthcare, are more likely to see providers who are not part of research institutions, and are less likely to be referred to or to join clinical trials, all of which may contribute to worse outcomes. Adolescents are treated by both adult and pediatric teams, following either adult or pediatric protocols. The type of team by which adolescents are treated (pediatric teams, or “combined” teams) may also impact the outcome. An unpublished survey by the EBMT (Dini) showed that 67% of patients aged 14-18 years old who received allogeneic hematopoietic stem cell transplantation (HSCT) for 2nd CR ALL from 1996 to 2005 that was reported to the EBMT registry had been treated by pediatric teams only, while the remaining 33% had been treated by adult teams [1].

Recent European studies have shown better outcomes in adolescents treated with pediatric protocols as compared to those treated with adult ones [2-5].
Adolescents should be referred to research treatment teams that have experience in the management of peediatric ALL, and they should be enrolled in international cooperative studies.  Molecular, genetic, and proteomic evaluation may cast further light on the causes of the rather striking decrease in survival that is seen as the patient progresses from childhood to adolescence.

Keywords

acute lymphoblastic leukemia, adolescents, pediatric ALL protocols, allogeneic hematopoietic stem cell transplantation, allo-HSCT


References

1. Dini G, Banov L, Dini S. EBMT Paediatric Diseases Working Party. Where should adolescents with ALL be treated? Bone Marrow Transplant. 2008 Oct;42 Suppl 2:35-9.

2. Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A et al.   Adolescents with Acute Lymphoblastic Leukaemia: outcome on UK National Paediatric (ALL 97) and Adult (UKALL XII/E2993) trials. Pediatric Blood Cancer. 2007;48:254-261.

3. Ramanujachar R, Richards S, Hann I, and Webb D. Adolescents with Acute Lymphoblastic Leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatric Blood Cancer. 2006;47:748-756.  

4. Testi AM, Valsecchi MG, Conter V, Vignetti M, Nigro LL, Locatelli F at al. Differences in outcome of adolescents with acute lymphoblastic leukaemia enrolled in paediatric (AIEOP) and adult (GIMEMA) protocols. Blood. 2004;104:539a.

5. De Bont JM, Holt B, Dekker AW, vanderDoes-vanderBerg A, Sonneveld P, Pieters R, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukaemia treated on paediatric vs adult protocols in the Netherlands. Leukemia. 2004;18:2032-2035.

Back to the list